Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Coherus Oncology, Inc.

CHRS Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2016โ€“FY2025

Last close ยท Oct 23, 2026

$1.01

3.8%
Compare
Revenue Total sales reported in the income statement.
$42.2M
59.8% vs prior year
Operating margin Operating income as a share of revenue.
โˆ’429.5%
327.1ย pts
Net income Profit after all expenses, interest and tax.
$168M
489.4%
Free cash flow Cash from operations minus capital spending.
โ€”
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$156M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$4.12 EPS (TTM)

What Coherus Oncology, Inc. does

No business description yet.

Legal name
Coherus Oncology, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Mar 9, 2026
Accession ยท CIK
0001104659-26-025308
0001512762

Revenue and margins

Coherus Oncology, Inc. had $42.2M of revenue in fiscal 2025, up 59.8% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โ€” in fiscal 2025, โ€” of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Coherus Oncology, Inc. returned โ€” to shareholders in fiscal 2025. The diluted share count rose 2.3%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Coherus Oncology, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $417M$192M$118M$126M$172M
Interest coverage โˆ’11.5xโˆ’7.9xโˆ’5.0xโˆ’18.6xโˆ’20.1x
Current ratio 3.6x2.7x1.4x1.2x1.5x
Quick ratio 3.4x2.5x1.2x1.2x1.4x
Total assets $679M$481M$630M$449M$258M
Total liabilities $582M$618M$823M$581M$197M
Shareholders' equity $97.7Mโˆ’$137Mโˆ’$193Mโˆ’$132M$61.0M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”โ€”โ€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ“ โœ“ โœ• โœ• โœ• โœ“ โœ“
Cash from operations is positive โœ• โœ• โœ• โœ“ โœ“ โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โœ• โœ• โœ“ โœ• โœ• โœ• โœ“ โœ“ โœ“
Cash from operations exceeds net income โœ• โœ“ โœ“ โœ• โœ“ โœ“ โœ“ โœ“ โœ• โœ•
Debt fell relative to assets โ€” โ€” โ€” โœ• โ€” โ€” โ€” โ€” โ€” โ€”
Current ratio rose โ€” โœ“ โœ• โœ“ โœ“ โœ• โœ• โœ• โœ• โœ“
Share count didn't rise โ€” โœ• โœ• โœ• โœ• โœ“ โœ• โœ• โœ• โœ•
Gross margin rose โ€” โ€” โ€” โ€” โœ• โœ• โœ• โœ• โœ“ โœ“
Revenue rose relative to assets โ€” โœ• โœ• โœ“ โœ• โœ• โœ• โœ• โœ• โœ“
F-score โ€” / 32 / 71 / 75 / 84 / 82 / 81 / 82 / 83 / 85 / 8
Accruals ratio 70.2%โˆ’22.2%โˆ’38.2%24.2%โˆ’3.5%โˆ’32.8%โˆ’8.7%โˆ’11.3%9.1%86.7%
Altman Z'' โˆ’10.18โˆ’20.17โˆ’43.01โˆ’1.343.67โˆ’3.25โˆ’9.61โˆ’9.10โˆ’13.65โˆ’20.15

10 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $190M $1.6M $0.0M $356M $476M $327M $211M $257M $26.4M $42.2M
Gross profit โ€” โ€” โ€” $339M $438M $269M $141M $98.3M $17.7M $28.4M
Research and development $254M $162M $110M $94.2M $143M $363M $199M $109M $91.8M $109M
Operating income โˆ’$116M โˆ’$232M โˆ’$204M $108M $156M โˆ’$264M โˆ’$257M โˆ’$203M โˆ’$200M โˆ’$181M
Interest expense $8.0M $9.6M $9.7M $17.6M $21.2M $23.0M $32.5M $40.5M $10.7M $9.0M
Pretax income โ€” โˆ’$238M โˆ’$209M $92.8M $136M โˆ’$287M โˆ’$292M โˆ’$238M โˆ’$215M โˆ’$183M
Income tax $0.0M $0.0M $0.0M $2.9M $3.5M $0.0M $0.0M โˆ’$0.4M $0.0M $0.0M
Net income โˆ’$127M โˆ’$238M โˆ’$209M $89.8M $132M โˆ’$287M โˆ’$292M โˆ’$238M $28.5M $168M
Diluted EPS โˆ’$3.04 โˆ’$4.48 โˆ’$3.22 $1.23 $1.62 โˆ’$3.81 โˆ’$3.76 โˆ’$2.53 $0.25 $1.43
Diluted shares 0.04B 0.05B 0.07B 0.07B 0.08B 0.08B 0.08B 0.09B 0.11B 0.12B
Cash flow
Cash from operations โˆ’$253M โˆ’$200M โˆ’$159M $28.4M $154M โˆ’$37.4M โˆ’$241M โˆ’$175M โˆ’$20.4M โˆ’$139M
Capital expenditure $6.5M $4.6M $0.8M $1.8M $7.2M $1.3M $2.0M $0.3M โ€” โ€”
Free cash flow โˆ’$259M โˆ’$205M โˆ’$160M $26.5M $147M โˆ’$38.7M โˆ’$243M โˆ’$175M โ€” โ€”
Depreciation and amortization $3.0M $3.4M $3.2M $3.3M $2.9M $3.5M $3.6M $3.2M $1.6M $1.3M
Stock-based compensation $27.4M $33.4M $34.8M $33.6M $38.2M $51.4M $50.7M $43.1M $27.8M $17.0M
Balance sheet
Cash and short-term investments $125M $127M $72.4M $178M $541M $417M $192M $118M $126M $172M
Total debt โ€” โ€” $0.0M $73.7M โ€” โ€” โ€” โ€” โ€” โ€”
Finance lease liabilities โ€” โ€” โ€” $0.0M $1.4M $1.2M $2.6M $1.1M โ€” โ€”
Current assets $161M $145M $84.4M $343M $767M $602M $381M $476M $342M $207M
Current liabilities $56.4M $28.4M $33.3M $115M $146M $165M $139M $332M $283M $140M
Inventory โ€” โ€” $1.7M $9.8M $44.2M $37.6M $38.8M $62.6M $4.2M $3.2M
Property and equipment, net $10.8M $12.8M $6.7M $5.8M $10.1M $7.8M $8.8M $5.1M $2.6M $1.3M
Goodwill $0.9M $0.9M $0.9M $0.9M $0.9M $0.9M $0.9M $0.9M โ€” โ€”
Intangible assets $2.6M $2.6M $2.6M $2.6M $2.6M $3.6M $5.9M $71.7M $24.8M $20.0M
Total assets $178M $163M $99.5M $409M $842M $679M $481M $630M $449M $258M
Total liabilities $159M $132M $138M $304M $561M $582M $618M $823M $581M $197M
Shareholders' equity $20.5M $30.5M โˆ’$38.6M $105M $281M $97.7M โˆ’$137M โˆ’$193M โˆ’$132M $61.0M
Margins
Gross margin โ€” โ€” โ€” 95.2% 92.1% 82.4% 66.8% 38.2% 66.9% 67.2%
Operating margin โˆ’61.0% โˆ’14,918.8% โ€” 30.3% 32.9% โˆ’80.8% โˆ’121.7% โˆ’79.0% โˆ’756.6% โˆ’429.5%
EBITDA margin โˆ’59.4% โˆ’14,700.4% โ€” 31.2% 33.5% โˆ’79.7% โˆ’120.0% โˆ’77.7% โˆ’750.5% โˆ’426.4%
Net margin โˆ’67.0% โˆ’15,306.6% โ€” 25.2% 27.8% โˆ’87.9% โˆ’138.2% โˆ’92.5% 108.0% 398.4%
FCF margin โˆ’136.3% โˆ’13,165.7% โ€” 7.5% 30.9% โˆ’11.9% โˆ’115.2% โˆ’68.1% โ€” โ€”
Returns
Return on capital โ€” โ€” โ€” 8,631.1% โ€” โ€” โ€” โ€” โ€” โ€”
Return on capital employed โˆ’94.9% โˆ’173.0% โˆ’308.8% 36.7% 22.5% โˆ’51.3% โˆ’75.1% โˆ’68.2% โˆ’120.6% โˆ’153.6%
Return on equity โˆ’620.3% โˆ’932.9% โ€” 269.7% 68.5% โˆ’151.6% โ€” โ€” โ€” โ€”
Return on assets โˆ’71.3% โˆ’139.6% โˆ’159.8% 35.3% 21.1% โˆ’37.8% โˆ’50.3% โˆ’42.8% 5.3% 47.5%
Return on tangible equity โˆ’750.6% โˆ’883.0% โ€” 88.4% 47.7% โˆ’307.8% โ€” โ€” โ€” 409.7%
Growth
Revenue growth โ€” โˆ’99.2% โˆ’100.0% โ€” 33.6% โˆ’31.4% โˆ’35.4% 21.9% โˆ’89.7% 59.8%
Net income growth โ€” โ€” โ€” โ€” 47.2% โˆ’317.1% โ€” โ€” โ€” 489.4%
EPS growth โ€” โ€” โ€” โ€” 31.7% โˆ’335.2% โ€” โ€” โ€” 472.0%
FCF growth โ€” โ€” โ€” โ€” 453.7% โˆ’126.4% โ€” โ€” โ€” โ€”
Share count change โ€” 26.8% 22.4% 12.5% 14.1% โˆ’9.6% 2.9% 21.3% 21.7% 2.3%
Financial health
Net debt / EBITDA โ€” โ€” โ€” โˆ’0.9x โ€” โ€” โ€” โ€” โ€” โ€”
Debt / equity โ€” โ€” โ€” 0.7x โ€” โ€” โ€” โ€” โ€” โ€”
Interest coverage โˆ’14.5x โˆ’24.3x โˆ’21.1x 6.1x 7.4x โˆ’11.5x โˆ’7.9x โˆ’5.0x โˆ’18.6x โˆ’20.1x
Current ratio 2.9x 5.1x 2.5x 3.0x 5.3x 3.6x 2.7x 1.4x 1.2x 1.5x
Quick ratio 2.9x 5.1x 2.5x 2.9x 5.0x 3.4x 2.5x 1.2x 1.2x 1.4x
Capital allocation
Capex / revenue 3.4% 293.9% โ€” 0.5% 1.5% 0.4% 1.0% 0.1% โ€” โ€”
Stock comp / revenue 14.4% 2,146.3% โ€” 9.4% 8.0% 15.7% 24.0% 16.8% 105.4% 40.2%
Quality scores
Piotroski F-score โ€” 2.0 1.0 5.0 4.0 2.0 1.0 2.0 3.0 5.0
Altman Z'' โˆ’10.2 โˆ’20.2 โˆ’43.0 โˆ’1.3 3.7 โˆ’3.3 โˆ’9.6 โˆ’9.1 โˆ’13.6 โˆ’20.2
Accruals ratio 70.2% โˆ’22.2% โˆ’38.2% 24.2% โˆ’3.5% โˆ’32.8% โˆ’8.7% โˆ’11.3% 9.1% 86.7%

Source: SEC EDGAR XBRL filings (CIK 0001512762). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open